Alnylam Pharmaceuticals (NASDAQ: ALNY) STOCK RECOMMENDATION
| Idea | BUY |
| Buy Range | 270 – 275 |
| Target | 305 – 310 |
| StopLoss* | below 260 |
| Duration | 12-14 Trading Days |
| Potential Returns | 12% – 13% |
| Idea | Buy Range | Target | StopLoss* | Duration | Potential Returns |
| BUY | 270 – 275 | 305 – 310 | below 260 | 12-14 Trading Days | 12% – 13% |
* Once the first target hit, reset the StopLoss at your buying price.
Our recommendations are authentic and transparent. Find this recommendation posted in Tradingview. Be assured such records are permanent and irreversible.
Alnylam Pharmaceuticals (NASDAQ: ALNY) STOCK OVERVIEW
Alnylam Pharmaceuticals, Inc., founded in 2002 and headquartered in Cambridge, Massachusetts, is at the forefront of biopharmaceutical innovation, specializing in ribonucleic acid interference (RNAi) therapeutics. The company’s portfolio includes groundbreaking treatments such as ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis, alongside GIVLAARI for acute hepatic porphyria and OXLUMO for primary hyperoxaluria type 1. Alnylam’s commitment to advancing medicine is further exemplified through its strategic collaborations with industry leaders like Regeneron Pharmaceuticals and Roche, enhancing the development of therapies for a range of challenging diseases. With an expansive pipeline targeting conditions from Alzheimer’s disease to chronic hepatitis B, Alnylam continues to redefine the therapeutic landscape.
| Stock Data | |
| NASDAQ Symbol | ALNY |
| Sectoral Index | Biotechnology |
| 52 Weeks High | 274.93 |
| 52 Weeks Low | 141.975 |
Alnylam Pharmaceuticals (NASDAQ: ALNY) - RELATIVE STRENGTH
Relative Performance - Last 1 Year
Alnylam Pharmaceuticals — NASDAQ —
Alnylam Pharmaceuticals (NASDAQ: ALNY) - DAILY TECHNICAL ANALYSIS
- The stock price has encountered several rejections around the 212 level, leading to subsequent corrections.
- After establishing a Double Bottom pattern, the price attempted to reverse the downward trend but was unable to do so, facing rejection at the 200 level.
- Consequently, the stock underwent another correction.
- Following this, the price entered a consolidation phase, forming a Box pattern for a while.
- In a surprising turn, the price gapped up significantly and broke through its former strong resistance area, remaining above it.
- Following a brief pullback, the price resumed its upward trajectory, supported by solid trading volume.
Alnylam Pharmaceuticals (NASDAQ: ALNY) - Technical Indicator ADX&DI
- Increasing ADX value above 20, indicated the strength of the trend, thereby uptrending ADX confirms the bullish or bearish supportive decisions. Along with the rising ADX, and the +DI is above (or crossing) -DI, indicates the long trades should be favoured.
Alnylam Pharmaceuticals (NASDAQ: ALNY) - Technical Indicator EMA Cross
- The short length exponential moving average (10 EMA) has crossed the long length exponential moving average (20 EMA) from the below, generates bullish signal. Last day’s candle has closed above all these moving averages. This suggests buyers are taking interest in this stock.
Alnylam Pharmaceuticals (NASDAQ: ALNY) - Technical Indicator RSI
- Current RSI of this stock is 71.21, which indicates the strength of buyers.
CONCLUSION - Alnylam Pharmaceuticals (NASDAQ: ALNY) STOCK PRICE FORECAST
Based on our stock trading advice in USA, Alnylam Pharmaceuticals stock price target will be USD 305 – USD 310 in the next 12-14 trading sessions.
A1 Trading Advice